|
As on 19-May-2022
|
|
|
|
The Board, based on the recommendation of the Audit Committee, has re-appointed M/s. Praveen & Madan, Chartered Accountants as the statutory auditors of theCompany for a second term of five years to hold office from the conclusion of the 47th AGM to be held on July 28, 2022 till the conclusion of the 52nd AGM ofthe Company to be held in the year 2027, subject to approval of shareholders of the Company.
|
|
|
|
|
|
|
Corporate Professionals Capital Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulation 3(1) and Regulation 4 readwith Regulation 15(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendmentthereto for the attention of Public Shareholders of Advik Capital Ltd ("Target Company").
|
|
|
|
|
|
|
Inter alia, approved: 1. Recommended a final dividend of Rs. 10 /- per equity share of Rs. 2/- each (i.e. 500%) for the financial year 2021-22. The same will be payable after it is approved by the shareholders at the ensuing Annual General Meeting. 2. Re-appointment of Statutory Auditors Re-appointment of M/s. N.M Raiji & Co., Chartered Accountants, Mumbai (Firm Registration No.108296W), based on the recommendation of Audit Committee, as the statutory auditors of the Company for a second term of five consecutive years from the conclusion of the ensuing 42nd Annual General Meeting tiff the conciusion of 47 Annual General Meeting to be held in the year 2027, subject to approval of the Shareholders at the ensuing Annual General Meeting. 3. Appointment of Additional Director Appointment of Mr. Rakesh Goyal (DIN: 07977008) as an additional director designated as Whole-time Director ? Operations for a period of 5 years, effective from June 1, 2022 to May 31 2027, based on the recommendation of Nomination and Remuneration Committee and subject to approval of shareholders of the Company at the ensuing Annual General Meeting. 4. Appointment of Chief Financial Officer (CFO): Appointment of Ms. Kanchan Shinde as CFO of the Company, based on the recommendation of Nomination and Remuneration Committee and Audit Committee, with immediate effect in place of Mr. Kirat Patel, who has relinquished the position of CFO with immediate effect.
|
|
|
|
|
|
|
Asahi Songwon Colors Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2022, inter alia, has approved thefollowing:1. The Board of Directors of the Company has recommended a Final Dividend of Rs. 0.50 per equity share (5.00%) of face value of Rs. 10 /- per equityshares for the financial year 2021-2022, subject to approval of members of the Company at the ensuing Annual General Meeting (AGM). Final Dividend, if approvedby the shareholders at the ensuing AnnualGeneral Meeting, will be paid within 30 days of the Annual General Meeting date. 2. Buyback of the fully paid up equityshares of the Company of face value Rs. 10 /- each.
|
|
|
|
|
|
|
The Board of Directors of the Company, at its meeting held today, based on the recommendation of the Audit Committee have recommended the re-appointment ofMessers. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No. 304026E/E300009), Chennai as the Statutory Auditors of the Company for a secondterm of five consecutive years i.e. from the conclusion of 73rd Annual General Meeting till the conclusion of 78th Annual General Meeting under Section 139 ofthe Companies Act, 2013. Their appointment will be subject to the approval of the shareholders.
|
|
|
|
|
|
|
Intimation of resignation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, of Ms. Saumya Goel from theposition of Company Secretary & Compliance Officer is attached.
|
|
|
|
|
|
|
Avonmore Capital & Management Services Ltd has informed BSE that a Meeting of the Board of Directors of the Companyis scheduled to be held on May 27, 2022,inter alia, to transact the following business:1. To consider and approve the Audited Financial Results (Standalone as well as Consolidated) for the Quarter andFinancial Year ended March 31, 2022 and to consider and take on record Annual Accounts for the Financial Year 2021-22.2. To consider a proposal of buyback ofEquity Shares of the Company.Further, the Trading Window shall continue to remain closed for all the insiders, i.e. for its Promoters and PromoterGroup,Directors, KMPs, Officers, Designated Employees and such other designated persons of the company till the 48 hours from the conclusion of Board Meetingi.e. May 27, 2022. During the closure of Trading Window, insiders have been advised not to deal in Equity Shares of the Company.
|
|
|
|
|
|
|
Outcome of Board Meeting-Intimation of Appointment of Internal Auditors
|
|
|
|
|
|
|
Re-appointment of Statutory Auditors for a second (2nd) term of five (5) consecutive years
|
|
|
|
|
|
|
Inter alia, approved: 1. Appointed Mr. Shiv Kumar Malu (DIN: 05345172) as additional (Non-Executive Independent) Director of the company subject to approval of shareholder at ensuing General Meeting. 2. Re-appointed Mr. Murarilal Mittal (DIN: 00010689) as Managing Director of the company for the further term of Five years subject to approval of shareholder at ensuing General Meeting 3. Appointed Mr. Sushil Sharda (DIN: 03117481) as additional (Whole-Time) Director - Finance of the company subject to approval of shareholder shareholders at ensuing Annual General Meeting 4. Appointed M/s. Borkar & Muzumdar, Chartered Accountant, has been appointed as Internal Auditors of the Company for the Financial Year 2022-23. D 5. Appointment of M/s. Dilip M. Bathija, Cost Accountant, has been appointed as Cost Auditors of the Company for the Financial Year 2022-23 6. Appointment of M/s. Mihen Halani & Associates, Company Secretaries, for conducting Secretarial audit for the Financial Year 2022-23 7. Reconstitution of Audit Committee, Nomination and Remuneration Committee 8. Constitution of Corporate Social Responsibility Committee.
|
|
|
|
|
|
|
Press release titled 'Biocon Biologics and Viatris Launch Abevmy? (bBevacizumab), Their Third Oncology Biosimilar, in Canada'.
|
|
|
|
|
|
|
Resignation of Ms. Divya Ajith (M. No. F11729) as Company Secretary and Compliance officer of the Company effective from close of business hours on May 19,2022.
|
|
|
|
|
|
|
Appointment of Mr. V. Srinivasan (M. No. A16430) as the Company Secretary & Compliance Officer of the Company effective from May 20, 2022
|
|
|
|
|
|
|
BSE Limited has informed the Exchange about completion of tenure of Justice Vikramajit Sen as Chairman on the Board of BSE Limited with effect from the closure of working hours on May 18, 2022
|
|
|
|
|
|
|
BSE Limited has informed the Exchange about completion of tenure of Justice Vikramajit Sen as Public Interest Director on the Board of BSE Limited with effect from the closure of working hours on May 18, 2022.
|
|
|
|
|
|
|
|
|
|
|
|